Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.38 |
| ▸ | MAOB | P27338 | 8/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855164 | 0.77 | MAOA (0.38) | MAOAMAOBALOX5CYP3A4KCNJ1 | |
| SCHEMBL855545 | 0.77 | TGM2 (0.40) | MAOAMAOBALOX5KCNJ1PDE3B | |
| SCHEMBL14719576 | 0.75 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL2044970 | 0.74 | LMNA (0.41) | MAOAMAOBALOX5CYP3A4KCNJ1 | |
| SCHEMBL855294 | 0.74 | MAOA (0.38) | MAOAMAOBALOX5KCNJ1 | |
| SCHEMBL2049186 | 0.69 | PGR (0.41) | MAOAMAOBALOX5CYP3A4KCNJ1 | |
| SCHEMBL16512964 | 0.68 | CYP3A4 (0.49) | MAOAMAOBCYP3A4KCNJ1KCNH2 | |
| SCHEMBL854099 | 0.66 | ALOX5 (0.39) | MAOAMAOBALOX5CYP3A4KCNJ1 | |
| SCHEMBL4168907 | 0.65 | — | — | |
| SCHEMBL26112753 | 0.63 | LMNA (0.41) | MAOAMAOBALOX5KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053365-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARMACEUTICAL, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053365-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARMACEUTICAL, INC. (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053365-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP3 | MAOA 587/4885MAOB 241/4885ALOX5 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.